Scarpone Michael, Rabago David, Snell Edward, Demeo Patrick, Ruppert Kristine, Pritchard Perry, Arbogast Gennie, Wilson John J, Balzano John F
Department of Orthopedics, Drexel University College of Medicine; Philadelphia, Pennsylvania, United States.
University of Wisconsin School of Medicine and Public Health, Department of Family Medicine, Madison, United States.
Glob Adv Health Med. 2013 Mar;2(2):26-31. doi: 10.7453/gahmj.2012.054.
Assess platelet rich plasma (PRP) injection for rotator cuff tendinopathy (RCT).
Prospective open label study with 1-year follow-up.
Participants recruited from an outpatient sports medicine clinic had clinically and magnetic resonance image (MRI)-demonstrated RCT refractory to physical therapy and corticosteroid injection. They received one ultrasound-guided injection of 3.0 mL of 1% xylocaine followed by 3.5 mL of PRP at the lesion and surrounding tendon.
0-10 visual analog scale (VAS; baseline, 8, 12, and 52 weeks).
functional shoulder tests assessing rotator cuff strength and endurance (at baseline and 8 and 12 weeks), MRI severity (1-5 points [at baseline and 4 and 8 weeks]), and patient satisfaction (52 weeks).
Eighteen participants with 19 assessed shoulders reported VAS pain score improvement from 7.5 ± 0.3 points to 0.5 ± 0.3 points by week 12 and 0.4 ± 0.2 (P = .0001) points at week 52. Functional outcomes significantly improved; the largest effect was seen in the external rotation test: 33.5 ± 5.7 seconds to 62.6 ± 7.2 seconds at week 12 (P = .0001). MRI appearance improved by 1 to 3 points in 16 of 18 assessed shoulders. Seventeen participants were "completely satisfied" (12) or "satisfied" (5). One participant was "unsatisfied."
A single ultrasound-guided, intralesional injection of PRP resulted in safe, significant, sustained improvement of pain, function, and MRI outcomes in participants with refractory RCT. Randomized multidisciplinary effectiveness trials that add ultrasound and validated clinical outcome measures are needed to further assess PRP for RCT.
评估富血小板血浆(PRP)注射治疗肩袖肌腱病(RCT)的效果。
前瞻性开放标签研究,随访1年。
从门诊运动医学诊所招募的参与者经临床和磁共振成像(MRI)证实患有RCT,且对物理治疗和皮质类固醇注射无效。他们在病变部位及周围肌腱接受一次超声引导下的注射,先注射3.0 mL 1%的利多卡因,随后注射3.5 mL PRP。
0至10分视觉模拟量表(VAS;基线、第8周、第12周和第52周)。
评估肩袖力量和耐力的功能性肩部测试(基线、第8周和第12周)、MRI严重程度(1至5分[基线、第4周和第8周])以及患者满意度(第52周)。
18名参与者的19个评估肩部报告称,VAS疼痛评分从7.5±0.3分在第12周时改善至0.5±0.3分,在第52周时为0.4±0.2分(P = .0001)。功能结局显著改善;在外旋测试中效果最为明显:第12周时从33.5±5.7秒提高至62.6±7.2秒(P = .0001)。18个评估肩部中的16个MRI表现改善了1至3分。17名参与者“完全满意”(12名)或“满意”(5名)。1名参与者“不满意”。
单次超声引导下的PRP病灶内注射在难治性RCT参与者中带来了疼痛、功能和MRI结局的安全、显著且持续的改善。需要进行添加超声和经过验证的临床结局测量的随机多学科有效性试验,以进一步评估PRP治疗RCT的效果。